Therapies to treat cardiovascular risk events differ depending on the age of an individual, and increases with age. This observation was made by Professor Wolfgang Koenig of University of Ulm, Germany, Professor James Shepherd, University of Glasgow, Scotland and Professor Paul Ridker, Brigham and Women's Hospital, USA during an educational event transmitted by Satellite link from Boston, USA to a global audience and monitored in Accra on Tuesday. It was on the theme "Extending the Boundaries of Cardiovascular Risk Intervention - Optimising Assessment and Treatment". The event was to address the need for effective therapeutic intervention to reduce the risk of Cardio-Vascular (CV), recognise co-morbidities that raise the risk of CV and additional risk factors not included in traditional risk assessment methods for effective treatment. They noted that many factors contributed to an individual's risk of developing CV, adding that compressive assessment and management of all risk factors were important for optimal CV risk reduction. They said the use of therapies was governed by guidelines but since traditional assessment methods might underestimate CV risk, many individuals at high risk of clinical events were not eligible for therapy under current guidelines. They therefore, called for proper management of CV risks to ensure the individual's life was assured. The live broadcast was sponsored by the management of AstraZeneca Pharmaceuticals, a South African drugs manufacturing company, which apart from manufacturing drugs also conducts research into medicines. Source: GNA